Mortality Similar With Torsemide, Furosemide for Patients Hospitalized With Heart Failure

TUESDAY, Jan. 24, 2023 (HealthDay News) -- For patients hospitalized for heart failure, all-cause mortality does not differ significantly at 12 months for those receiving torsemide or furosemide, according to a study published in the Jan. 17 issue of the Journal of the American Medical Association.

Robert J. Mentz, M.D., from the Duke Clinical Research Institute in Durham, North Carolina, and colleagues compared torsemide and furosemide among 2,859 patients hospitalized for heart failure in an open-label randomized trial conducted at 60 hospitals.

Originally published on consumer.healthday.com, part of the TownNews Content Exchange.

0
0
0
0
0

Load comments